Harbour Investments Inc. Acquires 326 Shares of Viking Therapeutics, Inc. $VKTX

Harbour Investments Inc. raised its holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 2.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,961 shares of the biotechnology company’s stock after purchasing an additional 326 shares during the quarter. Harbour Investments Inc.’s holdings in Viking Therapeutics were worth $396,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Quarry LP grew its stake in Viking Therapeutics by 1,621.4% in the 1st quarter. Quarry LP now owns 1,205 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,135 shares during the period. Parallel Advisors LLC grew its stake in Viking Therapeutics by 33.4% in the 2nd quarter. Parallel Advisors LLC now owns 1,818 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 455 shares during the period. Farther Finance Advisors LLC grew its stake in Viking Therapeutics by 571.4% in the 2nd quarter. Farther Finance Advisors LLC now owns 2,041 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,737 shares during the period. Flaharty Asset Management LLC bought a new position in Viking Therapeutics in the 1st quarter valued at $56,000. Finally, JNBA Financial Advisors bought a new position in Viking Therapeutics in the 1st quarter valued at $56,000. Institutional investors own 76.03% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on VKTX shares. Raymond James Financial cut their price target on Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating for the company in a research note on Thursday, July 24th. HC Wainwright reiterated a “buy” rating and set a $102.00 price target on shares of Viking Therapeutics in a research note on Monday, September 29th. Citigroup increased their price target on Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. BTIG Research reiterated a “buy” rating and set a $125.00 price target on shares of Viking Therapeutics in a research note on Monday, September 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $86.42.

Viking Therapeutics Stock Up 0.7%

Shares of NASDAQ VKTX opened at $33.75 on Tuesday. Viking Therapeutics, Inc. has a 52 week low of $18.92 and a 52 week high of $81.73. The business has a 50-day simple moving average of $29.14 and a two-hundred day simple moving average of $28.49. The company has a market cap of $3.79 billion, a P/E ratio of -22.06 and a beta of 0.64.

Viking Therapeutics (NASDAQ:VKTX) last issued its earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.14). During the same period last year, the company posted ($0.20) earnings per share. The company’s quarterly revenue was up NaN% on a year-over-year basis. Equities research analysts anticipate that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.